SCHEMBL2636019

SCHEMBL2636019

COC(=O)c1cc(OCC(=O)Nc2ccc(O)cc2)c2c(Cl)cc(Cl)cc2c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.50
MEN1 O00255 8/20 0.49
KMT2A Q03164 8/20 0.49
SMN1; SMN2 Q16637 2/20 0.48
NAMPT P43490 1/20 0.47
ALDH1A1 P00352 4/20 0.46
HPGD P15428 3/20 0.46
L3MBTL1 Q9Y468 2/20 0.44
CYP1A2 P05177 3/20 0.44
CYP2C19 P33261 3/20 0.44
CYP3A4 P08684 2/20 0.44
NPSR1 Q6W5P4 1/20 0.44
CETP P11597 1/20 0.44
MAPK1 P28482 1/20 0.43
LMNA P02545 2/20 0.43
CYP2C9 P11712 2/20 0.42
KDM4E B2RXH2 1/20 0.42
TSHR P16473 1/20 0.42
HSD17B10 Q99714 1/20 0.42
NPC1 O15118 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2635555 0.92 MAPT (0.52) MAPTMEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL2636505 0.90 NPC1 (0.50) MAPTMEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL2635404 0.89 MEN1 (0.54) MAPTMEN1KMT2ASMN1; SMN2NAMPT
SCHEMBL2635691 0.88 MAPT (0.47) MAPTMEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL2636074 0.85 NPC1 (0.55) MAPTMEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL2635387 0.84 ALDH1A1 (0.54) MAPTKMT2ASMN1; SMN2ALDH1A1HPGD
SCHEMBL2635915 0.84 MEN1 (0.45) MAPTMEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL2635692 0.84 RAB9A (0.44) MAPTMEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL2635701 0.81 MEN1 (0.60) MAPTMEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL2635943 0.81 TDP1 (0.49) MAPTMEN1KMT2ASMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120220577-A1 GLYCINE B ANTAGONISTS MERZ PHARMA GMBH & CO KGAA 2012-08-30 US disclosed
EP-2438037-A1 GLYCINE B ANTAGONISTS Merz Pharma GmbH & Co. KGaA (DE) 2012-04-11 EP disclosed
WO-2010139481-A1 GLYCINE B ANTAGONISTS MERZ PHARMA GMBH & CO. KGAA (DE) 2010-12-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120220577-A1 GLYCINE B ANTAGONISTS GLRB, GRIN2B, GLRA2 MAPT 1202/4885MEN1 932/4885KMT2A 2708/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.